Hong Kong's Legislative Council has approved a bill to implement tax relief measures, including one-time tax reductions and increased deductions, which will be reflected in taxpayers' assessments for the 2025/26 and 2026/27 tax years. In other news, Hengrui Medicine announced that its subsidiaries have received approval from the National Medical Products Administration to conduct clinical trials for three antibody drugs, including a novel treatment for advanced solid tumors. Additionally, a separate report mentions Qwen's advancements with Doubao and other tech news. AI
影响 This cluster has limited direct impact on AI operators, focusing more on policy and pharmaceutical developments.
排序理由 The cluster contains news about a government passing tax legislation and a pharmaceutical company advancing drug trials. [lever_c_demoted from significant: ic=1 ai=0.1]
- Adelimumab Injection
- Doubao
- Hong Kong
- Hengrui Medicine
- Legislative Council
- National Medical Products Administration
- Qwen
- Rilafuvir Alpha Injection
- Shanghai Shengdiya Pharmaceutical
- SHR-3821
- Suzhou Shengdiya Biomedical
AI 生成摘要 · Google Gemini · 来自 1 个来源。 我们如何撰写摘要 →